ABOUT ATRECA

We are a privately held biotechnology company developing novel therapeutics based on a deep understanding of the human immune response. Our proprietary technologies enable us to analyze clinically relevant immune responses of patients in a manner not possible before, driving the discovery and development of novel immunotherapies, including those in our lead programs in immuno-oncology.

Our Immune Repertoire Capture® (IRC™) and DeepSeq™ technologies deliver the sequences of antibodies and T cell receptors (TCRs) elaborated by informationally rich subsets of patient B and T cells with virtually no bias or error, enabling the identification and generation of functional and valuable human antibodies and TCRs directly from patients without prior knowledge of antigen. The unparalleled quality of our data transforms the discovery and development of therapeutics, vaccines, and diagnostics in multiple therapeutic areas where an immune response drives clinical outcomes.

Our technologies and approach have been validated repeatedly via partnerships with major pharmaceutical companies, non-profit foundations, academic institutions, and governmental entities. Our experienced leadership is supported by recognized technical advisors and leading investors dedicated to building a company with a worldwide and lasting impact on human health.

MANAGEMENT TEAM

Team Member Team Member Open
Close
Highlights
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit."
  • In tincidunt enim ut dui mollis, quis hendrerit nulla dictum."
  • Donec quis odio sed risus tempor imperdiet."

Tito A Serafini, PhD
President and CEO

Dr. Serafini is President, CEO, and a founder of Atreca. Before founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.

Dr. Serafini received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University, and he performed postdoctoral research at the University of California, San Francisco.

Team Member Team Member Open
Close
Highlights
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit."
  • In tincidunt enim ut dui mollis, quis hendrerit nulla dictum."
  • Donec quis odio sed risus tempor imperdiet. "

Jonathan Benjamin, MD PhD
Vice President, Clinical Research

Dr. Benjamin was previously Clinical Research Medical Director at Amgen where he designed and ran clinical trials of novel antibody constructs for hematologic malignancies. Previously, Dr. Benjamin was Assistant Professor of Medicine in the Division of Blood and Marrow Transplant at Stanford University School of Medicine.

Dr. Benjamin is board-certified in Hematology and Medical Oncology. He received his AB from Harvard College and MD and PhD from New York University. He completed his clinical training and performed post-doctoral research at the University of California, San Francisco.

Team Member Team Member Open
Close
Highlights
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit."
  • In tincidunt enim ut dui mollis, quis hendrerit nulla dictum."
  • Donec quis odio sed risus tempor imperdiet. "

Susan Berland, MBA
Chief Financial Officer

Susan Berland has over 20 years of experience in diverse areas of financial management and business transactions. Her senior management experience has included the position of Chief Financial Officer for Mendel Biotechnology and Poniard Pharmaceuticals. Earlier in her career she was Director in Monsanto’s corporate M&A group, and she subsequently led that company’s financial planning function through their merger with Pharmacia & Upjohn. She has worked in a variety of industries including life sciences (pharmaceuticals, molecular diagnostics, and medical devices), agriculture (seed operations, biotechnology, and crop protection), and telecommunications.

Ms. Berland holds MBA and BBA degrees from the University of Wisconsin – Milwaukee.

Team Member Team Member Open
Close
Highlights
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit."

Guy Cavet, PhD
Chief Technical Officer

Dr. Cavet is a founder of Atreca. He previously led informatics and computational biology at multiple biotechnology and information technology companies, including as a Vice President at Crescendo Bioscience, where he was instrumental in developing Vectra® DA, their marketed diagnostic product.

Prior to Atreca, Dr. Cavet was Chief Information Officer and Head of Computational Sciences at Nodality. He has also led informatics and computational biology teams at Genentech, Merck, and Rosetta Inpharmatics. Dr. Cavet received BS and PhD degrees in Biochemistry from Cambridge University, and he performed postdoctoral research at Stanford University.

Team Member Team Member Open
Close
Highlights
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit."

Paulette Dillon,
Sr. Vice President, Corporate Development

Mrs. Dillon is a founder of Atreca. Prior to her role at Atreca, Mrs. Dillon served sequentially as the Chief Business Officer of Nuon Therapeutics, Anacor, Avidia, and Celera Genomics, and held previous positions including Vice President at Exelixis and Hoffmann-La Roche where she led business development and strategic marketing for the Inflammatory Diseases Unit, and senior marketing and sales management positions at Syntex. She has led corporate/business development, commercial operations, global marketing and multiple product launches for start-up to large pharmaceutical and biotechnology companies. Mrs. Dillon received a BS from the University of California, Los Angeles.

Team Member Team Member Open
Close
Highlights
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit."
  • Donec quis odio sed risus tempor imperdiet. "

Daniel Emerling, PhD
Sr. Vice President, Research

Dr. Emerling is a founder of Atreca. Prior to founding Atreca, he was Senior Director of Pharmacology at Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Emerling was Senior Director of Preclinical Pharmacology at Renovis (and then at Evotec, its acquirer), which he joined as its first scientist.

Dr. Emerling received a BA in biochemistry from the University of California, Berkeley, and a PhD in neurobiology from the Massachusetts Institute of Technology, and he performed postdoctoral research at the University of California, Berkeley.

Team Member Team Member Open
Close
Highlights
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit."
  • In tincidunt enim ut dui mollis, quis hendrerit nulla dictum."

Norman Michael Greenberg, PhD
Chief Scientific Officer

Dr. Greenberg was previously Senior Vice President for Translational Medicine at Checkmate Pharmaceuticals, where he helped bring innovative immuno-oncology combinations to the clinic. Prior to Checkmate, Dr. Greenberg was Vice President of Global Research, Oncology, at MedImmune (AstraZeneca), where he spearheaded global research activities for immune-mediated and tumor-targeted therapies, a number of which are advancing in the clinic. He previously had served as Senior Director of Research, Oncology, at Pfizer, as a Full Member at the Fred Hutchinson Cancer Research Center in Seattle, and as a tenured Associate Professor at Baylor College of Medicine in Houston.

Dr. Greenberg received a BSc in microbiology and immunology from the University of Toronto and a PhD in microbiology and immunology from the University of British Columbia. He performed postdoctoral research at Baylor College of Medicine in Houston.

Team Member Team Member Open
Close
Highlights
  • In tincidunt enim ut dui mollis, quis hendrerit nulla dictum."

Wayne Volkmuth, PhD
Sr. Vice President, Informatics and Information Technology

Dr. Volkmuth is a founder of Atreca. Prior to founding Atreca, he was co-founder and President of Innectus, a provider of informatics software and services to emerging life sciences companies. Before leading Innectus, Dr. Volkmuth was Senior Director of Informatics and Information Technology at Renovis (and then at Evotec, its acquirer), which he joined as a startup.

Previously, he held research positions at Incyte and Ceres. Dr. Volkmuth received twin BS degrees in mathematics and physics from the University of Minnesota and MA and PhD degrees in physics from Princeton University, and he performed postdoctoral research at Stanford University.

Team Member Team Member Open
Close
Highlights
  • Donec quis odio sed risus tempor imperdiet. "
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit."

Jonathan Woo, PhD
Sr. Vice President, Finance and Strategy

Dr. Woo is a founder of Atreca. Prior to Atreca, he was an independent consultant to the biotechnology industry. Dr. Woo has held management positions of increasing responsibility at Bristol-Myers Squibb, Johnson & Johnson, Celera Genomics, and Avidia. Before entering the biotechnology industry, Dr. Woo was a management consultant with Mitchell Madison Group.

Dr. Woo received a BA in biochemistry from the University of California, Berkeley, a PhD in chemistry from Northwestern University, and he performed postdoctoral research at Memorial Sloan-Kettering Cancer Center.

BOARD OF DIRECTORS

Brian Atwood, Chairman
President and CEO, Founder of Cell Design Labs

Brian Atwood, Chairman
President and CEO, Founder of Cell Design Labs

Mr. Atwood is President and CEO as well as a founder of Cell Design Labs, a company focused on developing the human cell engineering technology from the UC San Francisco lab of Wendell Lim. Mr. Atwood is also a founder and Managing Director at Versant Ventures, a leading healthcare-focused venture capital firm, where he serves as a Managing Director. He has more than 15 years of operating experience in the biotechnology industry. Prior to launching his career in venture capital, Mr. Atwood was Founder, President, and Chief Executive Officer of Glycomed, a publicly traded biotechnology company.

Mr. Atwood also currently serves as a Board member at the public companies Clovis Oncology, Inc. (CLVS), OpGen, Inc. (OPGN), PhaseRx (PZRX), and Veracyte, Inc. (VCYT), where he is Chairman.

Mr. Atwood received a BS in Biological Sciences from the University of California, Irvine, an MS in Ecology from the University of California, Davis, and an MBA from Harvard Business School.

Franklin Berger, CFA
Former Managing Director at J.P. Morgan Securities

Franklin Berger, CFA
Former Managing Director at J.P. Morgan Securities

Mr. Berger is a biotechnology industry analyst with over twenty-five years of experience in capital markets and financial analysis. Mr. Berger was most recently a founder of the small-cap focused NEMO Fund at Sectoral Asset Management. He previously served as Managing Director, Equity Research, and Senior Biotechnology Analyst at J.P. Morgan Securities. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger has been involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities, including the Genentech initial public offering.

Mr. Berger currently serves as a director of the public biotechnology companies Five Prime Therapeutics, Immune Design, Proteostasis, and ESSA Pharma, and he previously served as a director of public biotechnology companies Seattle Genetics, Aurinia Pharmaceuticals, and VaxGen. He is a Founding Fellow of the Biotechnology Study Center at New York University School of Medicine. Mr. Berger received a BA in International Relations and an MA in International Economics from Johns Hopkins University, and an MBA from Harvard University.

David Lacey, MD
Former SVP of Discovery Research at Amgen

David Lacey, MD
Former SVP of Discovery Research at Amgen

Dr. Lacey, formerly Senior Vice President of Discovery Research at Amgen, possesses over 20 years of scientific and senior leadership experience within the life sciences, focused on creating new medicines to make a difference in the lives of patients worldwide. During his tenure at Amgen Dr. Lacey lead an organization of more than 1200 scientists across a portfolio of drug discovery and development projects in the therapeutic areas of hematology/oncology, inflammation, metabolic disorders, and neuroscience.

Prior to joining Amgen, he was on the faculty at Washington University in St. Louis, MO.

Dr. Lacey currently serves as a Board member for Nurix N.V. and Inbiomotion SL, and acts as an advisor to a number of academic institutions, biotechnology, and venture capital firms. Dr. Lacey received a bachelor’s degree in biology and an MD degree from the University of Colorado.

William H Robinson, MD PhD
Stanford University Professor and Founder of Atreca

William H Robinson, MD PhD
Stanford University Professor and Founder of Atreca

Dr. Robinson is a founder of Atreca and is currently Associate Professor of Medicine in the Division of Immunology and Rheumatology of the Department of Medicine at Stanford University. At Stanford, he is Director of the Stanford Osteoarthritis Initiative and a co-lead of the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus Network of the NIH. Dr. Robinson has been elected to the American Society of Clinical Investigation (ASCI) and the Henry Kunkel Society. He and his laboratory members invented the technology underlying Atreca’s Immune Repertoire Capture® technology.

Dr. Robinson is an inventor on twenty-one patent applications, and technologies developed in his Stanford and VA laboratories have been licensed to seven companies in the biotechnology industry.

Dr. Robinson was also a co-founder of Bayhill Therapeutics. Dr. Robinson received his BS, MD, and PhD degrees from Stanford University and completed his clinical training in internal medicine at the University of California, San Francisco.

Tito A Serafini, PhD
President and CEO, Founder of Atreca

Tito A Serafini, PhD
President and CEO, Founder of Atreca

Dr. Serafini is President, CEO, and a founder of Atreca. Before founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.

Dr. Serafini received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University, and he performed postdoctoral research at the University of California, San Francisco.

Lawrence Steinman, MD
Stanford University Professor and Founder of Atreca

Lawrence Steinman, MD
Stanford University Professor and Founder of Atreca

Dr. Steinman is a founder of Atreca and is currently the George A. Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics in the Stanford University School of Medicine. From 2002 to 2011, Dr. Steinman chaired the Stanford University Program in Immunology. Research in his laboratory led to the development of the blockbuster drug Tysabri® (natalizumab), which is used to treat patients with multiple sclerosis and Crohn’s Disease. He has received numerous awards for his research and has been elected to both the National Academy of Sciences and the National Academy of Medicine.

Dr. Steinman served on the board of directors and headed the scientific advisory board at Centocor for ten years, until the company was acquired by Johnson & Johnson. Dr. Steinman also co-founded and served as a director of Neurocrine Biosciences and Bayhill Therapeutics, and he co-founded Nuon Therapeutics. Dr. Steinman received a BA from Dartmouth College and an MD from Harvard University.

TECHNICAL ADVISORS

Mark M Davis, PhD
Director of the Stanford Institute for Immunity, Transplantation, and Infection at
Stanford University School of Medicine

Mark M Davis, PhD

Dr. Davis is Director of the Stanford Institute for Immunity, Transplantation, and Infection at Stanford University School of Medicine, where he is the Avery Family Professor of Immunology in the Department of Microbiology and Immunology. Dr. Davis is also an Investigator of the Howard Hughes Medical Institute. Dr. Davis is the author or co-author of more than 300 peer-reviewed articles and books, is a member of the National Academy of Sciences, and is the recipient of numerous awards and distinctions. Dr. Davis received his BA degree in molecular biology from Johns Hopkins University and his PhD degree in molecular biology from the California Institute of Technology. He was a postdoctoral fellow at the Laboratory of Immunology at the National Institutes of Health prior to joining Stanford.

Lawrence Fong, MD
Co-Leader, Cancer Immunotherapy Program, Helen Diller Family Comprehensive Cancer Center, and Efim Guzik Distinguished Professor in Cancer Biology at the University of California, San Francisco

Lawrence Fong, MD

Dr. Fong is Co-Leader, Cancer Immunotherapy Program, Helen Diller Family Comprehensive Cancer Center, and Efim Guzik Distinguished Professor in Cancer Biology at the University of California, San Francisco. He has served on National Cancer Institute (NCI) Steering Committees for Genitourinary Cancer (GUSC) and Investigational Drugs (IDSC)-Immunotherapy Task Force, and is a senior editor for Cancer Immunology Research. Dr. Fong is also the site principal investigator at UCSF for the NCI-sponsored Cancer Immunotherapy Trials Network (CITN). Dr. Fong received his BA degree from Columbia University and his MD degree from Stanford University, also completing an oncology fellowship at Stanford before joining the medical staff there in 1999. He joined UCSF in 2002.

Lori Kunkel, MD
Former Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals)

Lori Kunkel, MD

Dr. Kunkel has led successful clinical development programs at several life sciences companies, most recently as Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals). Prior to this, she was Vice President of Clinical Development at Xencor, Inc., and began her career in industry as a clinical scientist at Genentech. Dr. Kunkel has advised multiple firms, including Chiron (acquired by Novartis), Genentech/Roche, Salmedics (acquired by Celgene), and Syndax, and currently is an advisor to Curis, Inc., and Stemcentrx, Inc. She also serves on the boards of directors of Amphivena Therapeutics, Tocagen, Inc., Harpoon Therapeutics, and Loxo Oncology. Prior to entering the biotechnology industry, Dr. Kunkel spent ten years in academic medicine, during which time she served as Director of the Lymphoma Division in the Division of Hematology/Oncology at University of California, Los Angeles. She obtained her bachelor’s degree in biology from University of California, San Diego, and her MD degree from the University of Southern California. She is board-certified in internal medicine and held board certifications in hematology and oncology.

Lewis L Lanier, PhD
American Cancer Society Professor and the J. Michael Bishop MD Distinguished Professor and Chairman of the Department of Microbiology and Immunology at the University of California, San Francisco

Lewis L Lanier, PhD

Dr. Lanier is an American Cancer Society Professor and the J. Michael Bishop MD Distinguished Professor and Chairman of the Department of Microbiology and Immunology at the University of California San Francisco and is Leader of the Cancer Immunity Program of the UCSF Helen Diller Comprehensive Cancer Center and Director of the Parker Institute for Cancer Immunotherapy at UCSF. Dr. Lanier received his Ph.D. in Microbiology and Immunology from the University of North Carolina – Chapel Hill. After postdoctoral studies, first at the Lineberg Cancer Center at the UNC – Chapel Hill and then as a Damon Runyon – Walter Winchell Cancer Research Fellow at the University of New Mexico, he joined the Research & Development Department at the Becton Dickinson Monoclonal Center in Mountain View, California, advancing to Associate Director of Research and was a Becton Dickinson Research Fellow. In 1990, he joined the DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California, where he advanced to Director of Immunobiology. In 1999, Dr. Lanier joined the faculty of UCSF. His research group studies Natural Killer (NK) cells, which recognize and eliminate cells that have become transformed or infected by viruses. In recognition of his scientific contributions he was awarded the William B. Coley Award for Distinguished Research in Basic Tumor Immunology from the Cancer Research Institute in 2002, in 2005 was given the Rose Payne Award for contributions to the field of Immunogenetics by the American Society for Histocompatibility and Immunogenetics, in 2010 was elected to the US National Academy of Sciences, and in 2011 was named a Fellow of the American Academy of Microbiology and elected to the American Academy of Arts and Sciences. He was awarded the 2001 Distinguished Service Award from the American Association of Immunologists and served as President from 2006-2007. Dr. Lanier serves on the Scientific Advisory Board of several pharma and biotech companies and research institutes.